Article
Targeting a therapeutic LIF transgene to muscle via the immune system ameliorates muscular dystrophy
26 Jun 2019
Abstract excerpt
Many potentially therapeutic molecules have been identified for treating Duchenne muscular dystrophy. However, targeting those molecules only to sites of active pathology is an obstacle to their clinical use. Because dystrophic muscles become extensively inflamed, we tested whether expressing a therapeutic transgene in leukocyte progenitors that invade muscle would provide selective, timely delivery to diseased...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
